Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23726903 | 0.87 | ACHE (0.67) | KITACHEBACE1ENPP1AURKA | |
| SCHEMBL17030841 | 0.87 | KIT (0.53) | KITACHEBACE1MAP4K4MEN1 | |
| SCHEMBL31029781 | 0.87 | KIT (0.53) | KITACHEBACE1ENPP1MAP4K4 | |
| SCHEMBL30902145 | 0.87 | KIT (0.53) | KITACHEBACE1ENPP1MAP4K4 | |
| SCHEMBL17030847 | 0.87 | KIT (0.53) | KITACHEBACE1MAP4K4MEN1 | |
| SCHEMBL22029140 | 0.85 | KIT (0.52) | KITACHEBACE1ENPP1MAP4K4 | |
| SCHEMBL30826971 | 0.85 | KIT (0.52) | KITACHEBACE1ENPP1MAP4K4 | |
| SCHEMBL30080209 | 0.85 | TLR9 (0.65) | KITACHEBACE1ENPP1AURKA | |
| SCHEMBL23726540 | 0.85 | TLR9 (0.65) | KITACHEBACE1ENPP1AURKA | |
| SCHEMBL25656163 | 0.84 | ENPP1 (0.54) | KITACHEBACE1ENPP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | KIT 4739/4885ACHE 939/4885BACE1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.